Earnings call transcript: KMD Brands posts stronger FY 2026, shares slip
Source: Investing.com

KMD Brands reported FY2026 sales growth of 6.5% to NZD 1.053 billion and a 137.7% increase in underlying EBITDA to NZD 42 million, while gross margin rose 120bps to 57.7% and net debt fell to NZD 48.1 million. A NZD 462.7 million non-cash intangible impairment drove a statutory NZD 414.4 million net loss, contributing to a 1.49% share-price decline. FY2027 guidance targets sales of NZD 1.055-1.075 billion and EBITDA of NZD 52-55 million, but management remains cautious on consumer demand, tariffs and currency effects. The board is also evaluating non-binding external approaches, with no certainty of a transaction.
Analysis
KMD’s investable issue is not the accounting loss but whether the turnaround can convert margin gains into cash before the 2027 debt maturity wall becomes relevant. The guided profit step-up is unusually dependent on price, sourcing/FX and cost actions while top-line growth is essentially flat; this creates high operating sensitivity to even modest promotional pressure. The prior-year tariff recovery and late-period trading contribution also make the reported exit rate a weak base for extrapolation, while the impairment effectively confirms that historic acquisition-era returns will not be recovered. Price-to-book is therefore not a useful valuation anchor after the writedown.
Near term, the strategic review provides an asymmetric floor but not a reliable catalyst: indicative approaches can disappear, and a board unwilling to disclose timing leaves minority holders carrying execution and liquidity risk. The more consequential 1-3 month datapoints are holiday sell-through at Rip Curl, Ozmosis remediation, gross-margin realization excluding nonrecurring tariff effects, and supplier-payables normalization. A failure to reduce working capital despite stable inventory turns would be more bearish than a modest sales miss, as it would challenge the stated deleveraging path and potentially reintroduce equity-financing risk.
The contrarian case is that the market is valuing KMD as a distressed retailer despite a portfolio whose brands may be more valuable to strategic outdoor/apparel buyers than in a public conglomerate. But a buyer is likely to underwrite normalized brand EBITDA and working-capital needs rather than legacy book value; takeover speculation should be treated as a free option, not the core thesis. Shopify (SHOP) has negligible direct earnings sensitivity, though KMD’s digital conversion and fulfillment improvements are another small validation of Shopify’s enterprise migration proposition rather than a trade catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.08
Ticker Sentiment
Key Decisions for Investors
- KMD:ASX/NZX — maintain only a small event-driven long/watch position, entered after confirmation of first-half gross margin above the prior-year comparable excluding tariff refunds and net debt tracking toward <0.5x. Upside derives from a credible strategic bid or evidence that EBITDA converts to free cash flow; exit if working-capital absorption persists or covenant/liquidity language tightens.
- Do not use KMD’s stated book-value discount as a long signal. Re-underwrite on enterprise value versus sustainable EBITDA after lease obligations, seasonal working-capital needs and the remaining debt tranche; the impairment has materially reduced the relevance of asset-based valuation.
- For existing KMD holders, hedge consumer-discretionary beta over the next 3-6 months with a short in a broad retail proxy such as XRT rather than shorting SHOP. This isolates the idiosyncratic review/turnaround optionality from a deterioration in discretionary demand.
- Set a catalyst alert for a formal strategic-review update, holiday trading disclosure, and evidence of supplier-term stress. A binding proposal or asset-sale proceeds could justify increasing exposure; a guidance cut, margin miss after pricing actions, or further working-capital build falsifies the turnaround thesis.
More News
- CVS and UnitedHealth lost ground on Medicare ratings. Who gained?
- Coloplast down 4% as UBS sees limited upside after guidance cut
- DA Davidson cuts Akamai stock price target on shipment delays
- AI won’t pay off for the S&P 493 until CEOs rebuild the work
- Truist cuts James Hardie stock price target on homebuilding outlook
- Shopify: A $185B E-Commerce Empire Growing 30%+ Annually